Abbott helps people live fully through life-changing technology that makes you healthier. As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we’re committed to continuous improvement in the way patients and professionals measure, track and analyse glucose levels.
Abbott has provided a comprehensive range of blood glucose monitoring systems for people with diabetes for more than 20 years. In more recent years, Abbott has entered the sensor-based glucose monitoring device market with its revolutionary FreeStyle Libre flash glucose monitoring system which allows a user to monitor their glucose levels without fingerpricks while providing a much more complete view of glucose profile over time. Clinical studies have been performed to demonstrate benefits to the user in terms of improving their glucose control (Novel Glucose-Sensing Technology and Hypoglycaemia in Type 1 Diabetes: A Multicentre Non-masked, Randomised Controlled Trial (IMPACT), Lancet, Bolinder, J. et al, Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicentre, open-label, randomised controlled trial (REPLACE), Diabetes Therapy, Haak, T. et al).
Main tasks within the project will be to support the collation of clinical study data to establish a pooled and harmonised database as part of WP3, where Abbott will be represented as an industry co-lead. Abbott will also be an industry co-lead for WP5 where potential clinical studies will be discussed.